tirzepatide for iih Challenges in the management of idiopathic intracranial hypertension Tirzepatide Trial for Idiopathic Intracranial

That aligns with FDA guidance that compounded drugs are not FDA-approved even though they can be appropriate in certain circumstances

If you need long-term prokinetic therapy, GLP-1 medications might not be the best fit

Thyroid tumor warning: All semaglutide medications also carry an FDA boxed warning for a potential risk of thyroid C-cell tumors based on animal studies, although it is unknown whether this risk applies to humans

The study adhered to the principles of the Declaration of Helsinki and followed the STROBE guidelines (Strengthening the Reporting of Observational Studies in Epidemiology) for cohort study reporting [33]